Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
18.42 USD | +2.28% |
|
-2.36% | -33.69% |
06-04 | Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses | CI |
05-09 | Wedbush Adjusts Pharvaris' Price Target to $31 From $35, Maintains Outperform Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-33.69% | 969M | |
+38.65% | 39.1B | |
-9.33% | 38.76B | |
+26.82% | 31.24B | |
+10.72% | 25.9B | |
-13.50% | 25.8B | |
+43.56% | 14.06B | |
+32.89% | 13.12B | |
-8.41% | 11.32B | |
-13.42% | 10.68B |
- Stock Market
- Equities
- PHVS Stock
- News Pharvaris N.V.
- Pharvaris Narrows Q4 Net Loss; Hires New CFO